20S Constitutive Proteasome Assay Kit Reference: SBB-KP0038 South Bay Bio's kit is designed to test for specific activity of 20S proteasome. The kit provides purified 20S proteasome and is designed to test for Chymotrypsin-like activity (Suc-LLVY-AMC), Caspase-like activity of the proteasome subunits beta1/PSMB6 (LLE-AMC) and Chymotrypsin-like activity of beta5/PSMB5 (WLA-AMC). Additionally, the compound MG-132 is included, which can be used to inhibit the proteasome. All peptide substrates are conjugated to AMC, which upon proteasome catalyzed hydrolyses display fluorescence at Excitation=345nm, Emission=445nm; allowing for a real-time read out of 20S proteasome specific activity.
SARS-CoV-2 Inhibitor Screening Kit Reference: AG-48B-0001 Coronaviruses (CoVs) are enveloped non-segmented positive-sense single-stranded RNA viruses and can infect respiratory, gastrointestinal, hepatic and central nervous system of human and many other wild animals. Recently, a new severe acute respiratory syndrome beta-coronavirus called SARS-CoV-2 (or 2019-nCoV) has emerged, which causes an epidemic of acute respiratory syndrome (called coronavirus human disease 2019 or COVID-19). SARS-CoV-2 contains 4 structural proteins, including Envelope (E), Membrane (M), Nucleocapsid (N) and Spike (S), which is a transmembrane protein, composed of two subunits S1 and S2. The S1 subunit contains a receptor binding domain (RBD), which binds to the cell surface receptor Angiotensin-Converting Enzyme 2 (ACE2) present at the surface of epithelial cells, causing mainly infection of human respiratory cells. The SARS-CoV-2 Inhibitor Screening Kit contains key reagents required to facilitate identification of SARS-CoV-2 inhibitors. This inhibitor screen is based on a colorimetric ELISA kit, which measures the binding of the RBD of the Spike S protein from SARS-CoV-2 to its human receptor ACE2. This assay allows to identify and characterize the effect of different inhibitory molecules including antibodies or chemicals on the prevention of binding of SARS-CoV-2 virus to any ACE2-expressing cells.
NLRP3 Inflammasome Human Reagents Starter Set Reference: AG-44B-0010 The NLRP3 Inflammasome Human Reagents Starter Set is an all-in-one solution to study the NLRP3 inflammasome using Western blotting application. This starter set comprises our KO extract validated STANDARD antibodies against the key components of the NLRP3 inflammasome including NLRP3, Asc and Caspase-1, used and published by the experts in inflammasome research. It also contains two chemical compounds for priming and activation of the NLRP3 inflammasome. This economic starter set contains enough primary antibodies to perform at least 3 western blot experiments. Each antibody is available in 100µg catalog sizes for further experiments.
NLRP3 Inflammasome Mouse Reagents Starter Set Reference: AG-44B-0011 The NLRP3 Inflammasome Mouse Reagents Starter Set is an all-in-one solution to study the NLRP3 inflammasome using Western blotting application. This starter set comprises our KO extract validated STANDARD antibodies against the key components of the NLRP3 inflammasome including NLRP3, Asc and Caspase-1, used and published by the experts in inflammasome research. It also contains two chemical compounds for priming and activation of the NLRP3 inflammasome. This economic starter set contains enough primary antibodies to perform at least 3 western blot experiments. Each antibody is available in 100µg catalog sizes for further experiments.
FGL1 (human) Matched Pair Detection Set (mAb-based) Reference: AG-46B-0014 FGL1 (Fibrinogen-like protein 1, also called Hepatocyte-derived fibrinogen-related protein 1, HFREP-1 or Hepassocin) was initially identified as an overexpressed transcript in hepatocyte carcinoma and as a transcript enriched in regenerating liver. FGL1 is expressed at lower levels in brown and white adipose in the setting of liver injury. A low level expression of FGL1 is also observed in the pancreas. FGL1 is a 34kDa protein structurally similar to Angiopoietin-like factors 2, 3, 4 and 6, which regulate lipid metabolism and energy utilization. It was proposed that FGL1 is a member of an emerging group of proteins having potential roles in liver metabolism and liver regeneration. Recently, FGL1 has also been shown to be upregulated in human cancers and FGL1 is a major functional ligand of LAG-3. FGL1 interacts with LAG-3 in a MHC-II-independent manner and this interaction involves the FGL1 fibrinogen-like domain and the LAG-3 D1-D2 domain. FGL1-LAG-3 interaction blockade promotes tumor immunity by stimulating T cell expansion and activation. FGL1 forms two disulfide-linked homodimers and also higher molecular weight homooligomers that bind to LAG-3 much better than the dimeric forms. This binding to LAG-3 inhibits T cell responses. FGL1 is highly produced by human cancer cells, and elevated FGL1 in the plasma of cancer patients is associated with a poor prognosis and resistance to anti-PD-1/ B7-H1 therapy.